Microfluidics News Microfluidics News

  • Labcyte to Support GP-write Project Under New Agreement with Center of Excellence for Engineering Biology
    on 17th July 2018 at 12:00 am

    Labcyte Inc. today announced an agreement with the Center for Excellence in Engineering Biology (CEEB), an independent nonprofit that is managing initial planning and coordination of efforts for the Genome Project-write (GP-write). As part of the agreement, Labcyte will provide preferred pricing and in-kind support to researchers at qualified laboratories that are affiliated with and contributing to the mission and goals of GP-write. Additionally, Labcyte will provide selected researchers with early access to certain new products it develops. GP-write is an open, international scientific research project led by a multi-disciplinary group of scientific leaders who expect to oversee a reduction in the costs of engineering and testing of large genomes in cell lines by more than 1,000-fold within 10 years. Thus far, nearly 200 scientists affiliated with more than 100 organizations from 15 countries are involved in the project. Additionally, GP-write is developing new technologies, an ethical framework for genome-scale engineering and transformative medical applications. Labcyte is one of the founding members of the GP-write Industry Advisory Board, which is charged with developing complete workflow solutions for laboratories participating in the project. With its revolutionary acoustic liquid handling technology that enables the rapid synthesis and quality control of DNA assemblies, the company is a leader in enabling key steps for synthetic biology applications. Traditional DNA assembly methods require reactions of 10 to 20 microliters per well. Echo® Liquid Handlers from Labcyte reduce reaction volumes by up to 100x, enabling scientists to achieve drastically reduced reagent costs, along with faster, more accurate liquid transfers without the risk of contact-induced volume loss or contamination associated with tip-based instruments. Market-leading synthetic biology companies use Echo Liquid Handlers to automate gene synthesis with higher throughput and lower cost than they could with pipette-based systems. More information about the company’s solutions for synthetic biology can be found here. Labcyte Chief Executive Officer Mark Fischer-Colbrie commented, “Synthetic biology is another rapidly growing application of our touchless acoustic liquid handling systems which are broadly used in workflows ranging from drug discovery to personalized medicine to diagnostics, all of which achieve lower costs, faster assembly times and less reagent consumption. We are delighted to partner with GP-write and to support researchers working in this field. We look forward to seeing how we can innovate and push discoveries ahead faster together.” “Labcyte is an ideal partner for this important and far-reaching project, which aims to facilitate the use of biological engineering to address many global challenges facing humanity,” said Nancy J. Kelley, organizer and lead executive of the CEEB. “Labcyte’s revolutionary technology is uniquely suited to accelerate the work of the interdisciplinary research teams working around the globe that have engaged with GP-write.” About GP-write The GP-write Leadership Group includes Jef Boeke, Founding Director, Institute for Systems Genetics, NYU Langone Health; George Church, Core Faculty, Wyss Institute for Biologically Inspired Engineering, Harvard Medical School; Andrew Hessel, CEO, Humane Genomics, Inc. and Nancy J Kelley, President and CEO, Nancy J Kelley & Associates. GP-write is being implemented through the Center of Excellence for Engineering Biology, which supports the formation and work of multi-institutional and interdisciplinary research teams working in a highly integrated fashion, responsive to and engaged with a broad public outreach. To date, nearly 200 scientists, affiliated with more than 100 institutions/companies in 15 countries, are participating in GP-write. For more information about GP-write and the Center of Excellence for Engineering Biology, visit www.engineeringbiologycenter.org. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact for Labcyte Inc: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com PR Contact for GP-write: Carol Miller 202-306-0130 carolmiller100@gmail.com […]

  • Labcyte Reaches Agreement with Merck to Supply Acoustic-Mass Spectrometry Equipment
    on 17th April 2018 at 12:00 am

    Labcyte Inc. announced today that the company has entered an agreement with Merck, known as MSD outside the United States and Canada, to utilize Acoustic-Mass Spectrometry (Acoustic-MS) in drug discovery and development. Pioneered by Labcyte, acoustic droplet ejection (ADE) technology uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy. The technology does not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination, and enables miniaturization with reliable fluid transfers at volumes as low as 2.5 nanoliters. Labcyte has integrated its acoustic liquid handling technology with mass spectrometry in a process referred to as Acoustic-MS. Acoustic-MS has been shown to deliver high-quality data at extremely low volumes. As part of the agreement, prototype systems will be installed at select Merck sites where they will be evaluated within the context of existing and future workflows. “The ability for scientists to have full control over liquids with nanoliter resolution using our acoustic dispensing is forever changing broad areas of life sciences, from drug discovery to engineering biology,” said Mark Fischer-Colbrie, President and Chief Executive Officer at Labcyte. “Our continued effort to marry this novel capability with the power of mass spectrometry has created a new opportunity to achieve seminal advances driven by ultra-high throughput as well as exceedingly low costs and sample volumes. We look forward to working with Merck, a leading biopharmaceutical company, to build on the results achieved to date.” About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]

  • Dr. Sammy Datwani from Labcyte Inducted into the AIMBE College of Fellows
    on 9th April 2018 at 12:00 am

    Labcyte Inc. today announced that the American Institute for Medical and Biological Engineering (AIMBE) has inducted Sammy S. Datwani, Ph.D., Sr. Director, Principal Engineer, R&D at Labcyte to its College of Fellows. Dr. Datwani was nominated, reviewed, and elected by peers and members of the College of Fellows for contributions to leveraging microscale phenomena to enable label-free and high-throughput experimentation, screening and precision medicine. Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to "engineering and medicine research, practice, or education” and to "the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education." Dr. Datwani joined Labcyte in 2007 and is responsible for leading internal research programs and managing the advanced developments for the creation of new products and capabilities for the company in the arena of acoustic droplet ejection. Dr. Datwani has over twenty years of experience directing, managing, inventing and applying cutting edge research and developments in both industry and academia. Prior to Labcyte, he was a Senior Scientist and the Advanced Technologies Group Manager at Eksigent Technologies, LLC. From 2000 – 2003, he held the position of R&D Engineer in the Advanced Technology Group at Caliper Life Sciences and spearheaded the development of several LabChip® devices. Dr. Datwani graduated with honors from The Johns Hopkins University with a B.S. in Chemical and Biomolecular Engineering. He holds a M.S. degree from The Columbia University in Chemical Engineering with a concentration in Polymer Science. He earned his Ph.D. in Chemical and Biomolecular Engineering from The Johns Hopkins University. Since 2011, Dr. Datwani has held an appointment as an Adjunct Professor in the Department of Biomedical, Chemical & Materials Engineering at San Jose State University. Labcyte Chief Executive Officer Mark Fischer-Colbrie commented: “Sammy’s knowledge, skill-set and leadership put him at the top of his field, and we are proud to have him as part of our team. Over the past decade he has made many notable contributions to advancing our acoustic dispensing technology and helped us attain leadership in our field. I warmly congratulate him on behalf of all of us at Labcyte.” A formal induction ceremony was held during the AIMBE Annual Meeting at the National Academy of Sciences in Washington, DC on April 9, 2018. Dr. Datwani was inducted along with 156 colleagues who make up the AIMBE College of Fellows Class of 2018. About AIMBE AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. AIMBE’s mission is to recognize excellence, advance the public understanding, and accelerate medical and biological innovation. No other organization can bring together academic, industry, government, and scientific societies to form a highly influential community advancing medical and biological engineering. AIMBE’s mission drives advocacy initiatives into action on Capitol Hill and beyond. For more information about the AIMBE, please visit www.aimbe.org. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com PR Contact for AIMBE: Charlie Kim Director of Membership Services 202-496-9662 ckim@aimbe.org […]

  • Labcyte Acoustic Liquid Handlers Named Top Product in Lab Automation Conference Awards
    on 12th February 2018 at 12:00 am

    Labcyte Inc., was named the winner of two top awards at the International Conference of the Society for Laboratory Automation and Screening (SLAS), in recognition of the company's innovative acoustic liquid handlers. The company received a SLAS New Product Award for the Echo® 655T Liquid Handler, which was unveiled at the event along with the company's new Access™ Dual Robot System (DRS). The systems are key components of a new acoustic sample management solution that will support the next generation of pharmaceutical drug discovery which demands faster, high-throughput screens while consuming less sample. The company, along with its collaborators AstraZeneca, Brooks Life Sciences and Titian Software, introduced the new solution to attendees of SLAS2018 this week in San Diego. Labcyte also received the SelectScience® Reviewer's Choice Award for Drug Discovery & Development Product of the Year, based on thousands of product reviews written by scientists around the world on the scientific news and reviews site. The Echo 500 Series received strong marks for ease of use, service and value. According to one reviewer, the Echo Liquid Handler represents the "industry standard for touchless dispensing." Speaking at a press conference at the SLAS awards event, Labcyte CEO and President Mark Fischer-Colbrie said the acoustic droplet ejection technology pioneered by Labcyte, which uses the gentle energy of sound waves to move liquids at nanoliter resolution, was a "game changer" that has now become a mainstay of workflows across a wide range of application areas. Echo Liquid Handlers do not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination. The new Echo 655T system extends the benefits of contactless liquid transfer to the earliest stages of sample management to conserve sample material, preserve sample quality and deliver screening data of unparalleled quality, he said. Learn more about the new Access Dual Robot System and Echo 655T Liquid Handler. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]

  • Labcyte Introduces New Acoustic Sample Management Solution
    on 5th February 2018 at 12:00 am

    Labcyte Inc. today launched the Access™ Dual-Robot System (DRS) and the Echo® 655T Liquid Handler, key components of a new acoustic sample management solution that will support the next generation of pharmaceutical drug discovery as it demands faster, high-throughput screens while requiring less sample. The company, along with its collaborators AstraZeneca, Brooks Life Sciences and Titian Software, introduced the new solution to attendees of SLAS2018 this week in San Diego. Pioneered by Labcyte, acoustic droplet ejection (ADE) technology uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy. The technology does not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination, and enables assay miniaturization with reliable fluid transfers at volumes as low as 2.5 nanoliters. The Echo 655T Liquid Handler makes it possible to use acoustically compatible tubes for high-density sample storage, extending the benefits of contactless liquid transfer to the earliest stages of sample management to conserve sample material and preserve sample quality. The complete solution includes automated storage systems that allow for rapid retrieval of new FluidX™ AcoustiX™ Sample Tubes, both supplied by Brooks Life Sciences. Racked tubes are then transferred to the Access DRS workstation where the Echo 655T Liquid Handler transfers samples directly from AcoustiX tubes into assay-ready plates for high-throughput screening applications. The Access DRS is a highly flexible and scalable platform for automating both tube- and plate-based acoustic liquid handling workflows. Orders for and results from samples processed on the system are managed by software developed by Titian Software. The combination of acoustic tubes and acoustic liquid handling was first developed in tandem with AstraZeneca to automate its pharmaceutical compound management system using fully acoustic workflows. By implementing this innovative technology, the research organizations of leading biopharmaceutical companies like AstraZeneca could greatly reduce the frequency at which samples are replaced and lower the costs of maintaining large sample collections. "Working with Labcyte, we have created a cutting-edge capability that will provide an unparalleled level of quality in the screening data produced from our biological assays, deliver new ways of working across all our research centers, reduce cost, and transform our ability to identify new molecules that could become medicines of the future," said Clive Green, Executive Director Sample Management at AstraZeneca's IMED Biotech Unit. "We are incredibly delighted to partner with AstraZeneca, Brooks and Titian to bring unprecedented efficiency and quality in sample management and screening to laboratories around the world," said Mark Fischer-Colbrie, President and Chief Executive Officer at Labcyte. "Our new sample management solution provides a smarter approach to high-throughput screening and sets new standards for sample integrity, efficiency and data quality, while at the same time reducing costs throughout the process." Labcyte will now be offering the system as part of its range of modular, customizable automation platforms. For more information about Labcyte activities at SLAS2018, including a series of tutorial workshops, visit www.labcyte.com/slas2018/. Attendees can also visit representatives of the company at booth 915 / 921. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]